Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.
- DOI
- 10.1007/s40120-026-00905-3
- Published
- 2026 Jun
- Container
- Neurology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40120-026-00905-3,
title = {Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.},
author = {Matsumori Y and Nagy K and Takahashi A and Tanaka S and Takeshima T and Forero G and Bao J and Guo H and Ahmadyar G and de Abreu Ferreira R and Yamamoto T},
year = {2026},
journal = {Neurology and therapy},
doi = {10.1007/s40120-026-00905-3},
url = {https://doi.org/10.1007/s40120-026-00905-3}
}RIS
TY - JOUR TI - Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study. AU - Matsumori Y AU - Nagy K AU - Takahashi A AU - Tanaka S AU - Takeshima T AU - Forero G AU - Bao J AU - Guo H AU - Ahmadyar G AU - de Abreu Ferreira R AU - Yamamoto T PY - 2026 JO - Neurology and therapy DO - 10.1007/s40120-026-00905-3 UR - https://doi.org/10.1007/s40120-026-00905-3 ER -
APA
Y, M., K, N., A, T., S, T., T, T., G, F., J, B., H, G., G, A., R, D. A. F., & T, Y. (2026). Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.. Neurology and therapy. https://doi.org/10.1007/s40120-026-00905-3
Source records
- pubmed · retrieved 2026-09-27T08:10:59.870Z